Hormonal Optimization for Longevity

Hormonal optimization is one of the most impactful — and most nuanced — areas of longevity medicine. Hormone levels decline with age in predictable patterns: testosterone drops 1–2% annually in men from age 30; estrogen drops precipitously at menopause; DHEA peaks in the mid-20s and declines 80–90% by age 70; IGF-1 and growth hormone decline progressively; thyroid function becomes more variable. These declines are not merely statistical — they are mechanistically linked to muscle loss, fat gain, cognitive changes, cardiovascular risk, bone density reduction, and quality of life.

The therapeutic approach begins with comprehensive, properly timed lab work. Many practitioners underdiagnose hypogonadism because they rely on total testosterone alone; free testosterone, SHBG, LH, and FSH provide the full picture. Symptoms must be evaluated alongside numbers — two individuals with identical total testosterone can have radically different experiences based on SHBG and receptor sensitivity. Thyroid dysfunction (including subclinical hypothyroidism with TSH in the 3–5 range) is dramatically underdiagnosed in aging adults.

For men, testosterone replacement therapy (TRT) at physiological levels (targeting free testosterone in the upper-normal range) consistently improves body composition, bone density, sexual function, and quality of life. The cardiovascular evidence has shifted substantially — the TRAVERSE trial found no increased MACE risk with TRT in hypogonadal men with cardiovascular risk. Natural support through strength training, sleep optimization, and reducing visceral fat can meaningfully boost testosterone in those with borderline levels.

For women, the evidence for menopausal hormone therapy has been substantially rehabilitated since the original WHI misinterpretation. Bioidentical estradiol (transdermal or patch) combined with progesterone in women with a uterus appears to be cardiovascular-neutral or beneficial when initiated in the "window of opportunity" within 10 years of menopause. It robustly addresses bone density, cognitive function, vasomotor symptoms, and genitourinary health.